Frazier Life Sciences Management’s KalVista Pharmaceuticals KALV Stock Holding History

Frazier Life Sciences Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$99.9M	Sell	4,961,108 -78,759	-2%	-$1.27M	2.57%	12
2025 Q4	$81.4M	Hold	5,039,867	–	–	2.19%	12
2025 Q3	$61.4M	Buy	5,039,867 +152,000	+3%	+$2.1M	1.84%	13
2025 Q2	$55.3M	Hold	4,887,867	–	–	2.21%	13
2025 Q1	$56.4M	Hold	4,887,867	–	–	2.58%	11
2024 Q4	$41.4M	Buy	4,887,867 +1,200,000	+33%	+$12.4M	1.72%	16
2024 Q3	$42.7M	Hold	3,687,867	–	–	1.71%	19
2024 Q2	$43.4M	Hold	3,687,867	–	–	2.03%	14
2024 Q1	$43.7M	Buy	3,687,867 +65,573	+2%	+$874K	1.85%	17
2023 Q4	$44.4M	Buy	3,622,294 +383,435	+12%	+$3.49M	2.37%	14
2023 Q3	$31.2M	Hold	3,238,859	–	–	2.07%	14
2023 Q2	$29.1M	Hold	3,238,859	–	–	1.74%	15
2023 Q1	$25.5M	Hold	3,238,859	–	–	1.84%	12
2022 Q4	$21.9M	Buy	3,238,859 +1,666,667	+106%	+$8.93M	1.36%	20
2022 Q3	$22.8M	Hold	1,572,192	–	–	1.76%	17
2022 Q2	$15.5M	Hold	1,572,192	–	–	1.46%	18
2022 Q1	$23.2M	Buy	+1,572,192	New	+$22.6M	1.98%	16

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Frazier Life Sciences Management's KALV Position: Q1 2026 in Review

Frazier Life Sciences Management reduced its KalVista Pharmaceuticals (KALV) stake by 1.6% in Q1 2026, selling an estimated $1.27M and leaving 4,961,108 shares worth $99.9M. The position accounts for 2.57% of the portfolio, ranked #12.

Frazier Life Sciences Management first reported a position in KALV in Q1 2022 and has held it in 17 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Frazier Life Sciences Management held 4,961,108 shares of KalVista Pharmaceuticals worth $99.9M as of Q1 2026.
Frazier Life Sciences Management sold 78,759 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.27M.
KalVista Pharmaceuticals made up 2.57% of Frazier Life Sciences Management's portfolio in Q1 2026, its #12 holding.
Frazier Life Sciences Management first reported a position in KalVista Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.